Protein kinase R modulates c-Fos and c-Jun signaling to promote proliferation of hepatocellular carcinoma with hepatitis C virus infection.

por Takao Watanabe, Yoichi Hiasa, Yoshio Tokumoto, Masashi Hirooka, Masanori Abe, Yoshio Ikeda, Bunzo Matsuura, Raymond T Chung, Morikazu Onji
Publicado 2013

The long noncoding RNA of RMRP is downregulated by PERK, which induces apoptosis in hepatocellular carcinoma cells

por Atsushi Yukimoto, Takao Watanabe, Kotaro Sunago, Yoshiko Nakamura, Takaaki Tanaka, Yohei Koizumi, Osamu Yoshida, Yoshio Tokumoto, Masashi Hirooka, Masanori Abe, Yoichi Hiasa
Publicado 2021

Ileal mucosa-associated microbiota overgrowth associated with pathogenesis of primary biliary cholangitis

por Shogo Kitahata, Yasunori Yamamoto, Osamu Yoshida, Yoshio Tokumoto, Tomoe Kawamura, Shinya Furukawa, Teru Kumagi, Masashi Hirooka, Eiji Takeshita, Masanori Abe, Yoshiou Ikeda, Yoichi Hiasa
Publicado 2021

Hyperuricemia is a risk factor for the onset of impaired fasting glucose in men with a high plasma glucose level: a community-based study.

por Teruki Miyake, Teru Kumagi, Shinya Furukawa, Masashi Hirooka, Keitarou Kawasaki, Mitsuhito Koizumi, Yasuhiko Todo, Shin Yamamoto, Masanori Abe, Kohichiro Kitai, Bunzo Matsuura, Yoichi Hiasa
Publicado 2014

Impact of modified albumin–bilirubin grade on survival in patients with HCC who received lenvatinib

por Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masanori Atsukawa, Masashi Hirooka, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi, Kazuya Kariyama, Ei Itobayashi, Kazuto Tajiri, Noritomo Shimada, Hiroshi Shibata, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Shinya Fukunishi, Hideko Ohama, Kazuhito Kawata, Joji Tani, Shinichiro Nakamura, Kazuhiro Nouso, Akemi Tsutsui, Takuya Nagano, Tanaka Takaaki, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Kouji Joko, Yohei Koizumi, Yoichi Hiasa, Real-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Publicado 2021

Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study

por Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, Joji Tani, Kazuya Kariyama, Shinya Fukunishi, Masanori Atsukawa, Masashi Hirooka, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi, Ei Itobayashi, Kazuto Tajiri, Noritomo Shimada, Hiroshi Shibata, Hironori Ochi, Kazuhito Kawata, Satoshi Yasuda, Hidenori Toyoda, Tomoko Aoki, Takaaki Tanaka, Hideko Ohama, Kazuhiro Nouso, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Taeang Arai, Tomomi Okubo, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Koji Joko, Yoichi Hiasa, Masatoshi Kudo, The Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Publicado 2021